

CITATION REPORT

List of articles citing

Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure

DOI: 10.1016/j.joms.2009.03.050

Journal of Oral and Maxillofacial Surgery, 2010, 68, 243-53.

Source: <https://exaly.com/paper-pdf/48001530/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
372	Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure. 2010 , 2010, 376-377		1
371	Adverse effects of bisphosphonates. 2010 , 86, 421-35		108
370	Osteoporose [Risikofaktor in der Zahnheilkunde?]. 2010 , 107, 55-60		3
369	Glucocorticoid-induced osteoporosis: management update. 2010 , 8, 10-4		16
368	Characteristics of implant failures in patients with a history of oral bisphosphonate therapy. <i>Journal of Oral and Maxillofacial Surgery</i> , 2010 , 68, 508-14	1.8	33
367	Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure. <i>Journal of Oral and Maxillofacial Surgery</i> , 2010 , 68, 2232-40	1.8	90
366	Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. <i>Journal of Oral and Maxillofacial Surgery</i> , 2010 , 68, 2241-7	1.8	74
365	Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism. <i>Journal of Oral and Maxillofacial Surgery</i> , 2010 , 68, 2837-45	1.8	110
364	Bisphosphonate-Related Osteonecrosis of the Jaw Bone: Radiological Pattern and the Potential Role of CBCT in Early Diagnosis. 2010 , 1, e3		33
363	Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary. 2010 , 5, 355-62		28
362	Osteonecrosis of the jaws is associated with high-dose bisphosphonate treatment in patients with cancer. <i>Journal of the American Dental Association</i> , 2010 , 141, 887-8	1.9	2
361	[Jaw osteonecrosis induced by oral bisphosphonates: 12 cases]. 2010 , 111, 196-202		8
360	"Booby-Trap" - Dental implants at bay. <i>Saudi Dental Journal</i> , 2010 , 22, 99-100	2.5	
359	Effect of bisphosphonates on anodized and heat-treated titanium surfaces: an animal experimental study. 2011 , 82, 1035-42		29
358	Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review. 2011 , 7, 34-42		83
357	Long-term safety concerns of antiresorptive therapy. 2011 , 37, 387-400, vi		13
356	Adverse effects of bisphosphonates. 2011 , 7, 189-197		

355	Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence--a multi-centre study. 2011 , 39, 272-7	92
354	[Adverse effects of bisphosphonates]. 2011 , 7, 189-97	10
353	Safety of long-term bisphosphonate therapy for the management of osteoporosis. 2011 , 71, 791-814	59
352	Bisphosphonates and oral health: primer and an update for the practicing surgeon. 2011 , 23, 443-53	6
351	RETRACTED: Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetes. 2011 , 93, 166-173	16
350	Safety of bisphosphonates. <i>Bone</i> , 2011 , 49, 103-10	4-7 102
349	Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis. 2011 , 40, 277-84	63
348	Is rheumatoid arthritis a risk factor for oral bisphosphonate-induced osteonecrosis of the jaws?. 2011 , 77, 905-11	22
347	Prevalence of jaw osteonecrosis among patients receiving bisphosphonates in Riyadh. 2011 , 2, 29-32	1
346	Three-year experience with combined treatment with alendronate and alfacalcidol in Japanese patients with severe bone loss and osteoporotic fracture. 2011 , 7, 257-64	2
345	Robert Alexander Barter AM, MD, FRACP, FRCPA, FRCPath, FIAC. 2011 , 194, 51-51	
344	Impact of adverse news media on prescriptions for osteoporosis: effect on fractures and mortality. 2011 , 194, 51-2; author reply 52	1
343	Impact of adverse news media on prescriptions for osteoporosis: effect on fractures and mortality. 2011 , 194, 51-52	4
342	Correspondence (letter to the editor): Incidence of jaw necrosis is markedly higher. 2011 , 108, 356	
341	Bisphosphonate related osteonecrosis of the jaws: a review. 2011 , 28, 277-81	15
340	Current world literature. 2011 , 19, 322-8	
339	Oral health considerations in older women receiving oral bisphosphonate therapy. 2011 , 59, 916-22	13
338	Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers?. 2011 , 22, 100-5	36

337	Preventive protocol for tooth extractions in patients treated with zoledronate: a case series. <i>Journal of Oral and Maxillofacial Surgery</i> , 2011 , 69, e1-4	1.8	42
336	Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan. <i>Journal of Oral and Maxillofacial Surgery</i> , 2011 , 69, e364-71	1.8	83
335	Osteonecrosis of the jaw as a possible rare side effect of annual bisphosphonate administration for osteoporosis: A case report. 2011 , 5, 477		16
334	Current options for the management of postmenopausal osteoporosis. 2011 , 12, 2533-52		23
333	[Medically compromised patients in the dental office: demographics and progress in health care]. 2011 , 54, 1066-72		4
332	[Biphosphonate-induced femoral stress fractures : A new problem and knowledge so far - case report]. 2011 , 40, 1111-8		
331	Is bisphosphonate therapy for benign bone disease associated with impaired dental healing? A case-controlled study. 2011 , 12, 71		12
330	Oral bisphosphonate-related osteonecrosis of the jaws in rheumatoid arthritis patients: a critical discussion and two case reports. 2011 , 7, 7		23
329	Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat. 2011 , 26, 1871-82		154
328	Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. 2011 , 16, 121-32		99
327	Osteonecrosis of the jaw and the role of macrophages. 2011 , 103, 232-40		107
326	The growing role of epidemiology in drug safety regulation. 2011 , 22, 622-4		6
325	Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. <i>Journal of the American Dental Association</i> , 2011 , 142, 1243-51	1.9	242
324	The effects of osteoclast modifiers on the oral cavity: a review for prescribers. 2012 , 6, 337-41		9
323	Prothesendruckstellen als Risiko einer Bisphosphonat-assoziierten Kiefernekrose. 2012 , 121, 564-571		4
322	Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer. 2012 , 30, 1468-75		26
321	Forced eruption as an alternative to tooth extraction in long-term use of oral bisphosphonates: review, risks and technique. <i>Journal of the American Dental Association</i> , 2012 , 143, 1303-12	1.9	12
320	Three-year outcome of alendronate treatment in older Japanese women with osteoporosis. 2012 , 4, 11		

319	ANTIRESORPTIVE AGENTS: Authors' response. <i>Journal of the American Dental Association</i> , 2012 , 143, 736-739	1.9	
318	Regulatory innovation in postmarketing risk assessment and management. 2012 , 91, 555-7		19
317	Bisphosphonates as a risk factor for adverse orthodontic outcomes: a retrospective cohort study. 2012 , 142, 625-634.e3		16
316	The importance of a thorough medical and pharmacological history before dental implant placement. 2012 , 57, 388-92		6
315	Epidemiology and pathogenesis of osteonecrosis of the jaw. 2011 , 8, 90-6		122
314	Benefits and risks of bisphosphonate therapy for osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 2272-82	5.6	190
313	The outcomes of conservative and surgical treatment of stage 2 bisphosphonate-related osteonecrosis of the jaws: a case series. 2012 , 41, 1404-9		24
312	Is oral bisphosphonate-related osteonecrosis of the jaw an endemic condition?. 2012 , 78, 315-8		13
311	Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes. <i>Journal of Oral and Maxillofacial Surgery</i> , 2012 , 70, 1844-53	1.8	58
310	RANKL in the osteolysis of AES total ankle replacement implants. <i>Bone</i> , 2012 , 51, 546-52	4.7	39
309	The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells. 2012 , 40, e229-35		45
308	Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: technical report and follow up of 21 patients. 2012 , 40, 719-25		86
307	Histopathological features of bisphosphonate-associated osteonecrosis: findings in patients treated with partial mandibulectomies. 2012 , 114, 785-91		15
306	Bisphosphonate-related osteonecrosis of the jaws--a review. 2012 , 48, 938-947		97
305	Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without renal dysfunction: a retrospective study. 2012 , 29, 133-42		2
304	Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report. 2012 , 18, S1-15; discussion S13		42
303	Oral bisphosphonate-related osteonecrosis of the jaws: Clinical characteristics of a series of 20 cases in Spain. <i>Medicina Oral, Patologia Oral Y Cirugia Bucal</i> , 2012 , 17, e751-8	2.6	33
302	Etiopathogenesis and Clinical Aspects of BIONJ. 2012 , 73-84		

301 Endodontie bei älteren Patienten. **2012**, 6, 43-56

300	Bisphosphonate-associated osteonecrosis of the mandible: reliable soft tissue reconstruction using a local myofascial flap. 2012 , 16, 1143-52		44
299	Effects of alendronate on human osteoblast-like MG63 cells and matrix metalloproteinases. <i>Archives of Oral Biology</i> , 2012 , 57, 728-36	2.8	19
298	Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion. <i>Journal of Oral and Maxillofacial Surgery</i> , 2012 , 70, 325-30	1.8	10
297	The saxon bisphosphonate register - therapy and prevention of bisphosphonate-related osteonecrosis of the jaws. 2012 , 48, 349-54		54
296	Epidemiological aspects of rheumatoid arthritis patients affected by oral bisphosphonate-related osteonecrosis of the jaws. 2012 , 8, 5		14
295	New understanding and treatments for osteoporosis. 2012 , 41, 58-69		113
294	An epidemiological study of alendronate-related osteonecrosis of the jaws. A case series from the south-east of Scotland with attention given to case definition and prevalence. 2012 , 30, 171-82		59
293	Side Effects of Medical Cancer Therapy. 2013 ,		2
292	Conservative management of bisphosphonate-related osteonecrosis of the jaws: staging and treatment outcomes. 2013 , 49, 977-983		40
291	Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease. 2013 , 33, 2189-98		7
290	A brief review: characteristics of bisphosphonate-related osteonecrosis of the jaw (BRONJ) from the viewpoint of pathology. 2013 , 29, 105-110		2
289	Oral mucosa produces cytokines and factors influencing osteoclast activity and endothelial cell proliferation, in patients with osteonecrosis of jaw after treatment with zoledronic acid. 2013 , 17, 1259-66		21
288	Prospective biomarker evaluation in patients with osteonecrosis of the jaw who received bisphosphonates. <i>Bone</i> , 2013 , 57, 201-5	4.7	38
287	Osteonecrosis of the jaw onset times are based on the route of bisphosphonate therapy. <i>Journal of Oral and Maxillofacial Surgery</i> , 2013 , 71, 513-9	1.8	23
286	Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012. <i>Bone</i> , 2013 , 57, 423-8	4.7	95
285	The observational study of delayed wound healing after tooth extraction in patients receiving oral bisphosphonate therapy. 2013 , 41, 558-63		20
284	Mandibulectomy and free flap reconstruction for bisphosphonate-related osteonecrosis of the jaws. 2013 , 139, 1135-42		28

283	Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. 2013 , 126, 13-20		326
282	Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures. 2013 , 24, 697-705		27
281	Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges. 2013 , 24, 237-44		47
280	Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: a retrospective multi-hospital-based study of 87 Italian cases. 2013 , 24, 784-90		22
279	Bisphosphonate related osteonecrosis of the jaws: clinico-pathological investigation and histomorphometric analysis. 2013 , 115, 660-6		33
278	Reciprocating sliding wear behavior of alendronate sodium-loaded UHMWPE under different tribological conditions. 2013 , 33, 3001-9		13
277	Pathophysiology of BRONJ: Drug-related osteoclastic disease of the jaw. 2013 , 10, 1-8		30
276	Osteonecrosis of the Jaw and Atypical Femoral Fractures. 2013 , 1873-1908		2
275	A study of 225 patients on bisphosphonates presenting to the bisphosphonate clinic at King's College Hospital. <i>British Dental Journal</i> , 2013 , 214, E18	1.2	20
274	Bisphosphonate-related osteonecrosis of the jaw in four Nordic countries and an indication of under-reporting. 2013 , 71, 1386-90		14
273	Zahnärztliche Betreuung von Tumorpatienten. 2013 , 7, 357-378		
272	Pathologic fractures in bisphosphonate-related osteonecrosis of the jaw-review of the literature and review of our own cases. 2013 , 6, 147-54		21
271	Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice. 2013 , 28, 1631-40		79
270	BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate. 2013 , 28, 1319-27		39
269	Osteonecrosis of the external auditory canal associated with oral bisphosphonate therapy: case report and literature review. 2013 , 34, 209-13		17
268	Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report. 2013 , 39, 9-13		31
267	Recent Clinical Evidence in Bisphosphonate-related Osteomyelitis of the Jaw: Focus on Risk, Prevention and Treatment. 2014 , 9, 37-52		2
266	Bisphosphonate-related osteonecrosis of the jaw: specificities. 2014 , 8, 254		30

265	Male osteoporosis: clinical approach and management in family practice. 2014 , 55, 353-7		2
264	Preventive oral surgery before bisphosphonate administration to reduce osteonecrosis of the jaws. 2014 , 20, 809-14		
263	Bisphosphonate-related osteonecrosis of the palatal torus. 2014 , 76, 353-6		6
262	Current controversies in clinical management of postmenopausal osteoporosis. 2014 , 122, 437-44		5
261	Concomitant factors leading to an atypical osteonecrosis of the jaw in a patient with multiple myeloma. 2014 , 2014, 281313		3
260	Resource utilization in cancer patients with bisphosphonate-associated osteonecrosis of the jaw. 2014 , 20, 94-9		8
259	A large case-control study reveals a positive association between bisphosphonate use and delayed dental healing and osteonecrosis of the jaw. 2014 , 29, 1363-8		11
258	A C-terminal crosslinking telopeptide test-based protocol for patients on oral bisphosphonates requiring extraction: a prospective single-center controlled study. <i>Journal of Oral and Maxillofacial Surgery</i> , 2014 , 72, 1456-62	1.8	34
257	Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate. <i>Journal of Oral and Maxillofacial Surgery</i> , 2014 , 72, 76-82	1.8	46
256	Radiologic bone loss in patients with bisphosphonate-associated osteonecrosis of the jaws: a case-control study. 2014 , 18, 385-90		18
255	Principles of oral surgery for prevention of bisphosphonate-related osteonecrosis of the jaw. 2014 , 117, e429-35		45
254	How long should we treat?. 2014 , 25, 1659-66		5
253	American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. <i>Journal of Oral and Maxillofacial Surgery</i> , 2014 , 72, 1938-56	1.8	1448
252	Is bone turnover of jawbone and its possible over suppression by bisphosphonates of etiologic importance in pathogenesis of bisphosphonate-related osteonecrosis?. <i>Journal of Oral and Maxillofacial Surgery</i> , 2014 , 72, 903-10	1.8	30
251	Stem cell therapy for osteoporosis. 2014 , 12, 41-7		94
250	Incongruities in the AAOMS position paper: medication-related osteonecrosis of the jaw--2014 update. <i>Journal of Oral and Maxillofacial Surgery</i> , 2014 , 72, 2381	1.8	17
249	A model of BMD changes after alendronate discontinuation to guide postalendronate BMD monitoring. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 4094-100	5.6	8
248	Spontaneous Bisphosphonate-Induced Osteonecrosis of a Mid-Palatal Torus: A Case Report. 2014 , 4, 112-117		

247	The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 2729-35	5.6	22
246	Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population. 2014 , 25, 1503-11		26
245	Bisphosphonate-related osteonecrosis of the jaws is caused by dental procedures that violate oral epithelium; this is no longer a mysterious disease. 2014 , 117, 392-3		4
244	Long-term follow-up of jaw osteomyelitis associated with bisphosphonate use in a tertiary-care center. 2014 , 32, 18-22		4
243	Effect of dental implants on bisphosphonate-related osteonecrosis of the jaws. <i>Journal of Oral and Maxillofacial Surgery</i> , 2014 , 72, 1937.e1-8	1.8	43
242	The national-scale cohort study on bisphosphonate-related osteonecrosis of the jaw in Taiwan. 2014 , 42, 1343-52		11
241	Clinical treatment outcomes for 40 patients with bisphosphonates-related osteonecrosis of the jaws. 2014 , 113, 166-72		13
240	Long-term extension trials to prove the efficacy and safety of bisphosphonates. 2014 , 4, 35-43		
239	Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. 2014 , 161, 711-23		165
238	Surgical neurolysis for the treatment of neuropathic pain in 2 postmenopausal women with mandibular necrosis resulting from oral bisphosphonates. 2014 , 25, 1369-71		3
237	Periodontal Disease, Dental Implants, Extractions and Medications Related to Osteonecrosis of the Jaws. 2015 , 42, 878-80, 883-4, 887-89		3
236	Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events. 2015 , 1, 34		31
235	An osteonecrosis model induced by oral bisphosphonate in ovariectomised rats. 2015 , 21, 969-76		6
234	Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis. 2015 , 42, 922-32		52
233	Failure risk estimates after dental implants placement associated with plasma rich in growth factor-Endoret in osteoporotic women under bisphosphonate therapy. 2015 , 26, 749-55		20
232	Existing data sources for clinical epidemiology: Scandinavian Cohort for osteonecrosis of the jaw - work in progress and challenges. 2015 , 7, 107-16		12
231	Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. <i>Journal of Bone Metabolism</i> , 2015 , 22, 151-65	2.7	46
230	Osteonecrosis of the jaws. 2015 , 54, 1755-6		2

229	Pathological fracture of the coronoid process secondary to medication-related osteonecrosis of the jaw (MRONJ). 2015 , 10, 162-5		3
228	Effects of alendronate and pamidronate on apoptosis and cell proliferation in cultured primary human gingival fibroblasts. 2015 , 34, 1073-82		16
227	Epidemiology, Pharmacology and Clinical Characterization of Bisphosphonate-related Osteonecrosis of the Jaw. A Retrospective Study of 70 Cases. 2015 , 66, 139-147		1
226	Jaw Bone Samples From Bisphosphonate-Treated Patients: A Pilot Cohort Study. 2015 , 17 Suppl 2, e679-91		7
225	[Bisphosphonate-associated osteonecrosis of the jaw]. 2015 , 29, 171-8		1
224	High C-Terminal Cross-Linking Telopeptide Levels Are Associated With a Minimal Risk of Osteonecrosis of the Jaws in Patients Taking Oral Bisphosphonates and Having Exodontia. <i>Journal of Oral and Maxillofacial Surgery</i> , 2015 , 73, 1735-40	1.8	11
223	Drug induced osteonecrosis of the jaw. 2015 , 41, 455-64		55
222	Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. 2015 , 44, 568-85		176
221	Preventive Strategies for Patients at Risk of Medication-related Osteonecrosis of the Jaw. 2015 , 27, 527-36		13
220	The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors. 2015 , 27, 509-16		55
219	Impact of selective alveolar decortication on bisphosphonate burdened alveolar bone during orthodontic tooth movement. <i>Archives of Oral Biology</i> , 2015 , 60, 1681-9	2.8	7
218	[Bisphosphonate and denosumab-related osteonecrosis of the jaw: Epidemiology, diagnosis and management]. 2015 , 102, 1010-9		1
217	Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. 2015 , 30, 3-23		680
216	Risk Factors for Medication-Related Osteonecrosis of the Jaw. 2015 , 27-42		1
215	Medication-Related Osteonecrosis of the Jaws. 2015 ,		3
214	Implant Placement Adjacent to Successfully Treated Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ). <i>Journal of Oral Implantology</i> , 2015 , 41 Spec No, 377-81	1.2	5
213	Epidemiology, pharmacology and clinical characterization of bisphosphonate-related osteonecrosis of the jaw. A retrospective study of 70 cases. 2015 , 66, 139-47		9
212	Bisphosphonates: Possible Modes of Action and Implications for Dental Implant Treatment. A Review of the Literature 2016 , 03,		0

211	Osteoporosis treatment and medication-related osteonecrosis of the jaws. 2016 , 39, 47-8		0
210	BMP6-Engineered MSCs Induce Vertebral Bone Repair in a Pig Model: A Pilot Study. 2016 , 2016, 6530624		23
209	Concept, diagnosis and classification of bisphosphonate-associated osteonecrosis of the jaws. A review of the literature. <i>Medicina Oral, Patologia Oral Y Cirugia Bucal</i> , 2016 , 21, e260-70	2.6	17
208	Role of Teriparatide in Medication-Related Osteonecrosis of the Jaws (MRONJ). <i>Dentistry Journal</i> , 2016 , 4,	3.1	13
207	Diseases having an influence on inhibition of angiogenesis as risk factors of osteonecrosis of the jaw. 2016 , 42, 271-277		8
206	Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis. 2016 , 22, 324-9		29
205	BRONJ in patients with rheumatoid arthritis: a multicenter case series. 2016 , 22, 543-8		24
204	Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS). 2016 , 31, 336-40		55
203	Antiresorptiva-assozierte Kiefernekrose. 2016 , 9, 207-217		1
202	Dental implants in patients treated with antiresorptive medication - a systematic literature review. 2016 , 2, 9		45
201	Bisphosphonate-related osteonecrosis of the jaw: from the sine qua non condition of bone exposure to a non-exposed BRONJ entity. 2016 , 45, 20160049		22
200	Assessing the utility of serum C-telopeptide cross-link of type 1 collagen as a predictor of bisphosphonate-related osteonecrosis of the jaw: A systematic review and meta-analysis. <i>Journal of the American Dental Association</i> , 2016 , 147, 551-560.e11	1.9	16
199	Medication-related osteonecrosis of the jaw and dental implants failures: a systematic review.. <i>Journal of Oral Implantology</i> , 2016 ,	1.2	
198	Evaluation of surgical outcome and influencing risk factors in patients with medication-related osteonecrosis of the jaws. 2016 , 44, 1694-1699		28
197	Bisphosphonates, healthcare professionals and oral health. 2016 , 33, 135-43		4
196	Multipotent mesenchymal stromal cell sheet therapy for bisphosphonate-related osteonecrosis of the jaw in a rat model. 2016 , 42, 400-410		47
195	Osteoradionecrosis and medication-related osteonecrosis of the jaw: similarities and differences. 2016 , 45, 1592-1599		22
194	Bisphosphonate and Medication-Related Osteonecrosis of the Jaw: A Review. 2016 , 20, 305-314		31

193 Osteonecrosi dei mascellari sotto bifosfonati. **2016**, 15, 1-10

192	Epidemiological study of alendronate-related osteonecrosis of the jaw in the southeast of Scotland. 2016 , 54, 501-5		9
191	Bisphosphonate Treatment in Osteoporosis: Optimal Duration of Therapy and the Incorporation of a Drug Holiday. 2016 , 12, 66-73		15
190	Bisphosphonate drug holidays: we reap what we sow. 2016 , 27, 849-852		6
189	Simultaneous Application of Bone Morphogenetic Protein-2 and Platelet-Rich Fibrin for the Treatment of Bisphosphonate-Related Osteonecrosis of Jaw. <i>Journal of Oral Implantology</i> , 2016 , 42, 205-8	1.2	8
188	Zoledronate induces bisphosphonate-related osteonecrosis of the jaw in osteopenic sheep. 2016 , 20, 31-8		10
187	Awareness of medication related osteonecrosis of the jaws (MRONJ) amongst general dental practitioners. <i>British Dental Journal</i> , 2017 , 222, 121-125	1.2	21
186	Medication-Related Osteonecrosis of the Jaw and Dental Implants Failures: A Systematic Review. <i>Journal of Oral Implantology</i> , 2017 , 43, 51-57	1.2	23
185	Advanced Stage of Medication-Related Osteonecrosis of the Jaw Associated With Oral Bisphosphonates: Report of Three Cases. 2017 , 7, 64-72		
184	What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review. 2017 , 45, 1493-1502		54
183	Antiresorptive agent-related osteonecrosis of the jaw in osteoporosis patients from Asian countries. 2017 , 3, 64-74		3
182	Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. 2017 , 20, 8-24		125
181	Discontinuing oral bisphosphonate therapy during dental extraction does not prevent osteonecrosis of the jaw: A multicenter retrospective study of 341 patients with propensity score matching analysis. <i>Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology</i> , 2017 , 29, 522-526	0.4	3
180	Intervention to improve awareness of the risk factors for osteonecrosis of the jaw in patients under treatment with bisphosphonates. Randomised clinical trial. 2017 , 27, 352-360		1
179	Bone tissue response following local drug delivery of bisphosphonate through titanium oxide nanotube implants in a rabbit model. 2017 , 44, 941-949		12
178	Intervention to improve awareness of the risk factors for osteonecrosis of the jaw in patients under treatment with bisphosphonates. Randomised clinical trial. 2017 , 27, 352-360		
177	Osteoclast profile of medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis. 2017 , 15, 128		26
176	Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users. 2017 , 28, 2921-2928		21

175	Bisphosphonates in the treatment of osteoporosis: a review of skeletal safety concerns. 2017 , 12, 59-71	5
174	The utility of bone scintigraphy in the assessment of mandibular metabolism during long-term bisphosphonate administration. 2017 , 105, 382-390	12
173	Uncertainty of current algorithm for bisphosphonate-related osteonecrosis of the jaw in population-based studies: a systematic review. 2017 , 32, 584-591	13
172	Hyperbaric oxygen therapy and osteonecrosis. 2017 , 23, 141-151	20
171	Minor post-extraction complications other than BRONJ in older patients on oral bisphosphonates - a retrospective study. 2017 , 34, 171-179	
170	Appendix: Suggested Reading. 2017 , 699-741	
169	Dental students' knowledge of medication-related osteonecrosis of the jaw. 2017 , 11, 461-468	13
168	Effect of 1% sodium alendronate in the non-surgical treatment of periodontal intraosseous defects: a 6-month clinical trial. 2017 , 25, 310-317	14
167	Anti-resorptive treatment in osteoporosis and their deleterious effects on maxillary bone metabolism in clinical dentistry. 2017 , 185-209	
166	The Prevention of Medication-related Osteonecrosis of the Jaw. 2017 , 114, 63-69	20
165	Denosumab - a new medication in the treatment of postmenopausal osteoporosis. 2017 , 16, 75-78	
164	National Survey on Bisphosphonate-Related Osteonecrosis of the Jaws in Japan. <i>Journal of Oral and Maxillofacial Surgery</i> , 2018 , 76, 2105-2112	1.8 25
163	Update on osteoporosis treatment. 2018 , 150, 479-486	0
162	Update on osteoporosis treatment. 2018 , 150, 479-486	14
161	Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis. 2018 , 106, 469-480	15
160	Scoping Review of the Role of Shared Decision Making in Dental Implant Consultations. 2018 , 3, 130-140	5
159	Medication-related osteonecrosis of the jaw (MRONJ): realities, risks and responsibilities. 2018 , 45, 102-117	2
158	Bisphosphonate Drug Holiday and Fracture Risk: A Population-Based Cohort Study. 2018 , 33, 1252-1259	53

157	The Good and the Bad About the 2017 American College of Physicians Osteoporosis Guidelines. 2018 , 40, 168-176		9
156	Methotrexate-Related Lymphoproliferative Disorder in Patients With Osteonecrosis of the Jaw: A 3-Case Report and Literature Review. <i>Journal of Oral and Maxillofacial Surgery</i> , 2018 , 76, 97-111	1.8	10
155	Nasolabial Flap Improves Healing in Medication-Related Osteonecrosis of the Jaw. <i>Journal of Oral and Maxillofacial Surgery</i> , 2018 , 76, 877-885	1.8	21
154	Endodontics in Systemically Compromised Patients. 2018 , 263-292		2
153	Common Complications in Endodontics. 2018 ,		1
152	Detecting the earliest radiological signs of bisphosphonate-related osteonecrosis. <i>British Dental Journal</i> , 2018 , 224, 26-31	1.2	19
151	MRONJ risk of adjuvant bisphosphonates in early stage breast cancer. <i>British Dental Journal</i> , 2018 , 224, 74-79	1.2	16
150	Oral-Health-Related Quality of Life After Surgical Treatment of Osteonecrosis of the Jaws. 2018 , 29, 403-408		15
149	Treatment of Medication-Related Osteonecrosis of the Jaw and its Impact on a Patient's Quality of Life: A Single-Center, 10-Year Experience from Southern Italy. 2018 , 41, 111-123		14
148	Combination therapy of curcumin and alendronate modulates bone turnover markers and enhances bone mineral density in postmenopausal women with osteoporosis. 2018 , 62, 438-445		21
147	Bone regeneration with umbilical cord blood mesenchymal stem cells in femoral defects of ovariectomized rats. 2018 , 4, 95-101		12
146	Conservative surgical treatment of medication related osteonecrosis of the jaw (MRONJ) lesions in patients affected by osteoporosis exposed to oral bisphosphonates: 24 months follow-up. 2018 , 46, 1153-1158		16
145	Toxicity of Bone-Targeted Agents in Malignancy. 2018 , 439-460		
144	Dose-Intensity of Bisphosphonates and the Risk of Osteonecrosis of the Jaw in Osteoporosis Patients. 2018 , 9, 796		4
143	"Spontaneous" medication-related osteonecrosis of the jaw; two case reports and a systematic review. 2018 , 63, 441-454		5
142	Is the prevalence of the medication-related osteonecrosis of the jaws underestimated, evaluation in oncological and non-oncological disease. 2017 , 118, 724-731		10
141	The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects. 2018 , 13, e0196419		15
140	First reported bisphosphonate-related spontaneous oral-nasal fistula: a case report. 2019 , 48, 85-86		1

139	Pharmacoepidemiology and clinical characteristics of medication-related osteonecrosis of the jaw. 2019 , 41, 26		10
138	Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy: Systematic review and meta-analysis. <i>Journal of the American Dental Association</i> , 2019 , 150, 664-675.e8	1.9	6
137	Stem cells in Osteoporosis: From Biology to New Therapeutic Approaches. 2019 , 2019, 1730978		32
136	Using Pharmacy Data and Adherence to Define Long-Term Bisphosphonate Exposure in Women. 2019 , 25, 719-723		3
135	Medication-related osteonecrosis of the jaw after long-term bisphosphonate treatment in a cat. 2019 , 33, 862-867		7
134	Patient-Centered Risk Assessment in Implant Treatment Planning. 2019 , 34, 506-520		14
133	Fracture risk following intermission of osteoporosis therapy. 2019 , 30, 1733-1743		25
132	Risk factors of medication-related osteonecrosis of the jaw: a retrospective study in a Turkish subpopulation. 2019 , 45, 108-115		6
131	Medication-related osteonecrosis of the jaw: A literature review. 2019 , 61, 99-104		41
130	Preventing medication-related osteonecrosis of the jaw. 2019 , 365, l1733		6
129	Recommendations by the Spanish Society of Rheumatology on Osteoporosis. 2019 , 15, 188-210		2
128	Author's Reply to: Osimertinib and jaw osteonecrosis? A case report. 2019 , 145, 2006-2007		
127	Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 1595-1622	5.6	259
126	Oral Health and Healthy Aging. 2019 , 213-226		1
125	Diagnosis of B-cell lymphoproliferative disorder through concomitant management of medication-related osteonecrosis of the jaw: A case report. 2019 , 5, 100099		0
124	Osteonecrosis. 2019 , 263-282		
123	[Risk assessment of medication-related osteonecrosis of the jaw in general dental practice]. 2019 , 160, 243-251		2
122	Gene Variant Causing High Blood Pressure May Be Associated With Medication-related Jaw Osteonecrosis. 2019 , 33, 559-562		2

121	Database analysis of the risk factors of bisphosphonate-related osteonecrosis of the jaw in Hungarian patients. 2019 , 9, e025600	7
120	Rare adverse effects of bisphosphonate therapy. 2019 , 26, 335-338	6
119	Follow-Up of an Implant-Supported Rehabilitation After Long-Term Use of Alendronate. 2019 , 30, e793-e796	0
118	Prospect of mesenchymal stem cells in therapy of osteoporosis: A review. 2019 , 234, 8570-8578	50
117	Quantitation and distribution of metallic elements in sequestra of medication-related osteonecrosis of jaw (MRONJ) using inductively coupled plasma atomic emission spectroscopy and synchrotron radiation X-ray fluorescence analysis. 2019 , 37, 676-684	5
116	Recommendations by the Spanish Society of Rheumatology on Osteoporosis. 2019 , 15, 188-210	15
115	Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. 2019 , 127, 117-135	97
114	Osteoporosis therapy in patients with inflammatory rheumatic diseases and osteonecrosis of the jaw. 2020 , 79, 203-209	1
113	Dental Implant Treatment in Medically Compromised Patients. 2020 ,	
112	Secondary Nerve Reconstruction. 2020 , 514-521	
111	The effects of different doses of teriparatide on bisphosphonate-related osteonecrosis of the jaw in mice. 2020 , 26, 609-620	6
110	Complications of Dentoalveolar Surgery. 2020 , 32, 649-674	0
109	Surgical treatment of advanced medication-related osteonecrosis of the jaws: Comparison of soft tissue closure techniques and evaluation of side effects. 2020 , 48, 896-901	5
108	Mesenchymal stem cells: amazing remedies for bone and cartilage defects. 2020 , 11, 492	34
107	Dentists' knowledge about medication-related osteonecrosis of the jaw and its management. 2020 , 6, e04321	5
106	Chemical effect of bisphosphonates on the bone trabeculate of jaws via fractal dimension. 2020 , 58, 2013-2023	
105	Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw. 2020 , 12, 30	13
104	Quantitative bone single photon emission computed tomography analysis of the effects of duration of bisphosphonate administration on the parietal bone. 2020 , 10, 17461	3

103	Awareness of the risk of developing medication-related osteonecrosis of the jaw among bisphosphonate users. 2020 , 48, 300060520955066		0
102	Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors. 2020 , 8, 14		32
101	Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. 2020 , 26, 1784-1802		5
100	Therapeutic approach and management algorithms in medication-related osteonecrosis of the jaw (MONJ): recommendations of a multidisciplinary group of experts. 2020 , 15, 101		6
99	Medication-related osteonecrosis of the jaw. 2020 , 13, 207-212		
98	Tooth extractions in patients under antiresorptive therapy for osteoporosis: Primary closure of the extraction socket with a mucoperiosteal flap versus application of platelet-rich fibrin for the prevention of antiresorptive agent-related osteonecrosis of the jaw. 2020 , 48, 444-451		7
97	Korreliert die Prävalenz der bisphosphonatassoziierten Kiefernekrosen mit der Einnahmedauer der Bisphosphonate bei Tumor- und Osteoporosepatienten?. 2020 , 27, 8-18		
96	Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals. 2020 , 28, 4019-4029		10
95	A scorecard for osteoporosis in Canada and seven Canadian provinces. 2021 , 32, 123-132		3
94	Incidence of and risk for osteonecrosis of the jaw in Korean osteoporosis patients treated with bisphosphonates: A nationwide cohort-study. <i>Bone</i> , 2021 , 143, 115650	4-7	6
93	Osteonecrosis of the jaw associated with imatinib therapy in myeloproliferative neoplasm: a rare case report. 2021 , 131, e157-e162		1
92	Combined orthodontic and surgical treatment for a patient with Hallermann-Streiff-Francois syndrome, severe obstructive sleep apnea, and history of antiresorptive medication. 2021 , 159, 97-107		0
91	SIRT1 Gene SNP rs932658 Is Associated With Medication-Related Osteonecrosis of the Jaw. 2021 , 36, 347-356		7
90	Root canal treatment of compromised teeth as alternative treatment for patients receiving bisphosphonates: 60-month results of a prospective clinical study. 2021 , 54, 156-171		3
89	Is implant surgery a risk factor for osteonecrosis of the jaw in older adult patients with osteoporosis? A national cohort propensity score-matched study. 2021 , 32, 437-447		5
88	Osteonecrosis of the jaw in a patient under treatment of osteoporosis with oral bisphosphonate. 2020 , 11, e2020186		0
87	Effect of Bacterial Infection on Bone Quality and Structure in Osteonecrosis of the Jaw by Bisphosphonate (BP) Administration. <i>Journal of Hard Tissue Biology</i> , 2021 , 30, 323-330		0.4
86	Infektionen. 2021 , 171-214		

85	The treatment gap: The missed opportunities for osteoporosis therapy. <i>Bone</i> , 2021 , 144, 115833	4-7	5
84	A Clinical and Histological Study about the Socket Preservation in a Patient under Oral Bisphosphonates Treatment: A Case Report. <i>Biology</i> , 2021 , 10,	4-9	0
83	The awareness and practice of dentists regarding medication-related osteonecrosis of the jaw and its prevention: a cross-sectional survey. 2021 , 21, 155		0
82	The Effect of Drugs, Hormones, and Diet on Orthodontic Tooth Movement. 2021 , 199-215		
81	A SINGLE REFERENCE CENTER, 2 YEARS RETROSPECTIVE STUDY ON THE RISK FACTORS ASSOCIATED WITH ANTI-RESORPTIVE MEDICATION-RELATED OSTEONECROSIS OF THE JAWS IN OSTEOPOROTIC AND ONCOLOGICAL PATIENTS.		0
80	Application of Photodynamic Therapy in the Treatment of Osteonecrosis of the Jaw.		
79	The Treatment Gap in Osteoporosis. 2021 , 10,		4
78	Treatment of Refractory Medicine Related Osteonecrosis of Jaw With Piezosurgical Debridement and Autologous Platelet Rich Fibrin: Feasibility Study. 2021 ,		1
77	Characteristics of patients with osteonecrosis of the jaw with oral versus intravenous bisphosphonate treatment. 2021 , 43, 24		0
76	18 Years of Medication-Related Osteonecrosis of the Jaw (MRONJ) Research: Where Are We Now? An Umbrella Review. 2021 , 11, 8818		1
75	Bone Mineral Density Loss and Fracture Risk After Discontinuation of Anti-osteoporotic Drug Treatment: A Narrative Review. 2021 , 81, 1645-1655		1
74	Dentoalveolar Procedures in Immune Thrombocytopenia; Systematic Review and an Institutional Guideline. 2021 , 5, e489-e502		1
73	Extracellular vesicles from adipose tissue-derived stem cells alleviate osteoporosis through osteoprotegerin and miR-21-5p. 2021 , 10, e12152		15
72	Anti-resorptive Therapies. 2021 , 67-80		
71	The effect of drugs and diet on orthodontic tooth movement. 173-187		6
70	Toxicity of Bone-Targeted Agents in Malignancy. 2013 , 531-567		1
69	Epidemiology of Medication-Related Osteonecrosis of the Jaw. 2015 , 55-61		1
68	Bisphosphonate drug holidays: Risk of fractures and mortality in a prospective cohort study. <i>Bone</i> , 2020 , 138, 115431	4-7	2

67	Intérêt de la scintigraphie au technétium 99 métastable (99mTc) pour la prise en charge des ostéonécroses liées aux bisphosphonates. <i>Medicine Buccale Chirurgie Buccale</i> , 2011 , 17, 203-209		1
66	Bisphosphonate-related osteonecrosis of the jaws. A severe side effect of bisphosphonate therapy. <i>Acta Medica (Hradec Kralove)</i> , 2012 , 55, 111-5	0.8	25
65	Medication-Related Osteonecrosis of the Jaw Subsequent to Periimplantitis: A Case Report and Literature Review. <i>Journal of Oral Implantology</i> , 2020 ,	1.2	3
64	The Effect of Bisphosphonate on Bone Formation After Tooth Extraction in Ovariectomized Rats. <i>Journal of Hard Tissue Biology</i> , 2013 , 22, 493-500	0.4	2
63	Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2020 , 24, 1-314	4.4	30
62	Medication-related osteonecrosis of the jaw: Clinical and practical guidelines. <i>Journal of International Society of Preventive and Community Dentistry</i> , 2016 , 6, 97-104	1.1	84
61	Alendronate-associated osteonecrosis of the jaws: a review of the main topics. <i>Medicina Oral, Patologia Oral Y Cirugia Bucal</i> , 2014 , 19, e106-11	2.6	15
60	Review and update on drugs related to the development of osteonecrosis of the jaw. <i>Medicina Oral, Patologia Oral Y Cirugia Bucal</i> , 2020 , 25, e71-e83	2.6	33
59	Nonresolving Osteomyelitis of the Maxilla and Maxillary Sinus after Long-term Use of Oral Bisphosphonates. <i>International Journal of Head and Neck Surgery</i> , 2010 , 1, 107-110	0.1	1
58	Experience with the treatment of bisphosphonate-related osteonecrosis of the jaw. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2015 , 159, 313-7	1.7	3
57	Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2020 , 164, 100-107	1.7	7
56	Osteoporosis Management with Focus on Spine. 2021 , 61-92		
55	Review and Update of the Risk Factors and Prevention of Antiresorptive-Related Osteonecrosis of the Jaw. <i>Endocrinology and Metabolism</i> , 2021 , 36, 917-927	3.5	2
54	Effect of continuous and intermittent sodium alendronate oral dosing on post-extraction alveoli healing in rats. <i>Archives of Oral Biology</i> , 2021 , 132, 105291	2.8	1
53	Osteonecrosis of the jaw in a patient taking once-yearly infusion of zoledronic acid for osteopenia. <i>Case Reports in Clinical Medicine</i> , 2013 , 02, 535-537	0.1	
52	Bisphosphonate-related osteonecrosis of the jaws: A report on 30 cases. <i>Open Journal of Stomatology</i> , 2013 , 03, 247-254	0.2	1
51	Bisphosphonate-Associated Osteonecrosis of the Jaws. 929-940		
50	Management of the Patient Undergoing Radiotherapy or Chemotherapy. 2014 , 363-381		1

49	Ostéonécrose des maxillaires: quand l'ancien traitement avec bisphosphonates est connu. <i>Medecine Buccale Chirurgie Buccale</i> , 2014 , 20, 177-183		
48	Imaging Modalities and Characteristics in Medication-Related Osteonecrosis of the Jaw. 2015 , 63-77		
47	Epidemiology of Osteonecrosis of the Jaws from Antiresorptive Treatment. 2016 , 185-192		
46	Management of osteoporosis patients for prosthetic restoration. <i>Journal of Dental Rehabilitation and Applied Science</i> , 2016 , 32, 93-101	0.2	1
45	Oral and Maxillofacial Aspects of Bone Research. <i>Learning Materials in Biosciences</i> , 2017 , 125-137	0.3	
44	Mandible-Maxilla Osteonecrosis. 2017 , 472-473		
43	Mandible-Maxilla Osteonecrosis. 2018 , 199		
42	Osteoradionecrosis and Antiresorptive Drug-Related Osteonecrosis of the Jaws. 2019 , 91-101		
41	Bone Diseases and Dental Implant Treatment. 2020 , 73-101		1
40	Stress response in periodontal ligament stem cells may contribute to bisphosphonate-associated osteonecrosis of the jaw: A gene expression array analysis. <i>Molecular Medicine Reports</i> , 2020 , 22, 2043-2051	2.9	0
39	Managing Intraoral Lesions in Oral Cancer Patients in a General Dental Practice: An Overview. <i>Journal of the California Dental Association</i> , 2016 , 44, 85-92	4.3	3
38	[Bisphosphonate-related osteonecrosis of the jaw caused by implant: a case report]. <i>Hua Xi Kou Qiang Yi Xue Za Zhi = Huaxi Kouqiang Yixue Zazhi = West China Journal of Stomatology</i> , 2020 , 38, 460-463		
37	The incidence of medication-related osteonecrosis of the jaw following tooth extraction in patients prescribed oral bisphosphonates. <i>British Dental Journal</i> , 2021 ,	1.2	1
36	Osteonecrosis of the Jaws in Patients with Hereditary Thrombophilia/Hypofibrinolysis-From Pathophysiology to Therapeutic Implications.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	0
35	Medication-Related Osteonecrosis of the Jaw (MRONJ): A Review of Pathophysiology, Risk Factors, Preventive Measures and Treatment Strategies. <i>Saudi Dental Journal</i> , 2022 ,	2.5	0
34	Osteonecrosis of the Jaw. 2022 , 857-902		
33	Surgical Therapy in Patients With Medication-Related Osteonecrosis of the Jaw Is Associated With Disease Resolution and Improved Quality of Life: A Prospective Cohort Study.. <i>Journal of Oral and Maxillofacial Surgery</i> , 2022 ,	1.8	0
32	Medication Related Osteonecrosis of the Jaw: 2021 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons.. <i>Journal of Bone Metabolism</i> , 2021 , 28, 279-296	2.7	3

31	Medication-related osteonecrosis of the jaw: An update. <i>National Journal of Maxillofacial Surgery</i> , 2022 ,	0.7	0
30	Osteonecrosi delle ossa mascellari farmaco-relata: ruolo nella pratica clinica endocrinologica. <i>L Endocrinologo</i> , 2022 , 23, 156-162	0	0
29	Impacts of bisphosphonates on the bone and its surrounding tissues: mechanistic insights into medication-related osteonecrosis of the jaw.. <i>Archives of Toxicology</i> , 2022 , 1	5.8	1
28	American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaw-2022 Update.. <i>Journal of Oral and Maxillofacial Surgery</i> , 2022 ,	1.8	21
27	How Do Drugs Affect the Skeleton? Implications for Forensic Anthropology.. <i>Biology</i> , 2022 , 11,	4.9	0
26	Medication-Related Osteonecrosis of the Jaws: A Literature Review. <i>Journal of Oral Medicine and Pain</i> , 2022 , 47, 1-9	0.2	
25	Emerging antiresorptive medications and their potential implications for dental surgeries.. <i>Journal of the American Dental Association</i> , 2022 ,	1.9	0
24	Gradual, but Not Sudden, Dose-Dependent Increase of ONJ Risk With Bisphosphonate Exposure: A Nationwide Cohort Study in Women With Osteoporosis.. <i>Frontiers in Endocrinology</i> , 2021 , 12, 774820	5.7	1
23	Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by ECTS.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 ,	5.6	2
22	Evaluation of bone regeneration ability of Mg mesh coated with calcium phosphate by cyclic precalcification treatment. <i>Korean Journal of Dental Materials</i> , 2021 , 48, 229-244	0.3	
21	Medication-related osteonecrosis of the jaw after tooth extraction in patients receiving pharmaceutical treatment for osteoporosis: A retrospective cohort study. <i>Journal of Dental Sciences</i> , 2022 ,	2.5	0
20	Medication-Related Osteonecrosis of the Jaw in Dental Practice: A Retrospective Analysis of Data from the Milan Cohort. <i>Dentistry Journal</i> , 2022 , 10, 89	3.1	
19	Incidence and risk factors associated to Medication-Related OsteoNecrosis of the Jaw (MRONJ) in patients with osteoporosis after tooth extractions. A 12-months observational cohort study. <i>Journal of Stomatology, Oral and Maxillofacial Surgery</i> , 2022 ,	1.7	0
18	Zoledronate and lipopolysaccharide suppress osteoblast differentiation through downregulating phosphorylation of Smad in pre-osteoblastic MC3T3-E1 cells. <i>Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology</i> , 2022 ,	0.4	
17	Medication-related osteonecrosis of the jaw after dental clearance: prevalence in an oncology center. <i>Saudi Dental Journal</i> , 2022 ,	2.5	
16	A Multidisciplinary Pathway for the Diagnosis and Prosthodontic Management of a Patient with Medication-Related Osteonecrosis of the Jaw (MRONJ). 2022 , 12, 8202		
15	Current Status of the Diagnosis and Management of Osteoporosis. 2022 , 23, 9465		1
14	Duration and timing of bisphosphonate treatment as factors determining osteoblast mineralization. 2022 , 12, 575-579		

- 13 Advanced Hydrogel systems for mandibular reconstruction. **2023**, 21, 175-193 ○
- 12 Osteonecrosis of the jaw in primary dental care: Recognition and referral. **2022**, 11, 108-116 ○
- 11 Knowledge, Attitude, and Practices of Physicians and Dentists on Medication-related Osteonecrosis of Jaw (MRONJ): A Cross-Sectional Survey. ○
- 10 Awareness of patients receiving bisphosphonates: a cross-sectional study. 36, ○
- 9 Efficacy of Adjunctive Photobiomodulation in the Management of Medication-Related Osteonecrosis of the Jaw: A Systematic Review. **2022**, 40, 777-791 ○
- 8 Advancement in the Treatment of Osteoporosis and the Effects on Bone Healing. **2022**, 11, 7477 ○
- 7 Managing Intraoral Lesions in Oral Cancer Patients in a General Dental Practice: An Overview. **2016**, 44, 85-92 ○
- 6 Evaluation of Medication-Related Osteonecrosis of the Jaw (MRONJ) in Terms of Staging and Treatment Strategies by Dental Students at Different Educational Levels. **2023**, 59, 252 ○
- 5 Medication-Related Osteonecrosis of the Jaws (MRONJ) in Children and Young Patients: A Systematic Review. **2023**, 12, 1416 ○
- 4 Oral Manifestations Associated with Rheumatic Diseases. **2023**, 369-393 ○
- 3 Letter to editor in regard to Sunderasan et al. (<https://doi.org/10.1111/scd.12801>). ○
- 2 Successful New Dental Implant Installation in a Healed Site of Medication-Related Osteonecrosis of the Jaw: A Case Report. **2023**, 49, 117-123 ○
- 1 Medication-related osteonecrosis in torus palatinus: Report of a case and literature review. ○